JAZZ is down 3.88% today. Volume is 970.0K vs a 30-day average of 806.1K (1.20x).
Jazz Pharmaceuticals plc is scheduled to report earnings Mon, Nov 2, 2026 · after close. Analysts expect EPS of $-4.01 on revenue of about $1.23B. Stocks often move sharply on earnings day.
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combi…
HJazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced updated overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combi…
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and lowers the price target from $322 to $314.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 third quarter financial results on Monday, November 2, 2026, after the close of the U.S. financial …